Company Overview - Biophytis is a clinical-stage biotechnology company focused on developing therapeutics to slow degenerative processes associated with aging and improve outcomes for patients with age-related diseases, including severe respiratory failure due to COVID-19[5]. - The company is based in Paris, France, and Cambridge, Massachusetts, and aims to improve functional outcomes for patients suffering from age-related diseases[5]. - Biophytis' common shares are listed on Euronext Growth Paris (Ticker: ALBPS) and American Depositary Shares (ADSs) are listed on Nasdaq Capital Market (Ticker: BPTS)[5]. Drug Development - The leading drug candidate, Sarconeos (BIO101), is in a Phase 2 clinical trial for sarcopenia in the US and Europe, and is also being studied in a Phase 2-3 clinical trial for severe respiratory manifestations of COVID-19 in Europe, Latin America, and the US[5]. - A pediatric formulation of Sarconeos (BIO101) is being developed for the treatment of Duchenne Muscular Dystrophy (DMD)[5]. Annual General Meeting (AGM) - The Annual General Meeting (AGM) will be held on April 26, 2021, at 5:00 p.m. CET, behind closed doors due to COVID-19 restrictions[1][2]. - Shareholders are encouraged to vote in advance via mail, proxy, or the secure online platform VOTACCESS, with deadlines set for April 23 and April 25[4]. - The company has made available all legally required documents for shareholders' votes on its website[1]. - The notice of meeting was published in the French official legal bulletin, including information on how to vote at the AGM[3]. Forward-Looking Statements - The press release contains forward-looking statements that are subject to various risks and uncertainties, including those described in filings with the U.S. Securities and Exchange Commission[6].
Biophytis(BPTS) - 2020 Q4 - Annual Report